Hong Kong stock market's abnormal movement | Rongchang Biotechnology (09995.HK) opens nearly 5% higher, Thai Tesbi's treatment for Primary Sjgren's Syndrome Phase III clinical trial achieves primary endpoint.

date
16/08/2025
According to the Securities Times app, Rongchang Bio (09995.HK) opened nearly 5% higher, rising by 4.7% as of the time of publication, with a closing price of HK$71.35 and a total turnover of HK$118.41 million.